Erick Lucera Sells 2,362 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) CFO Erick Lucera sold 2,362 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total value of $48,113.94. Following the sale, the chief financial officer owned 121,563 shares of the company’s stock, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Erick Lucera also recently made the following trade(s):

• On Wednesday, May 13th, Erick Lucera sold 1,448 shares of Dyne Therapeutics stock. The shares were sold at an average price of $18.36, for a total transaction of $26,585.28.

Dyne Therapeutics Stock Up 1.6%

DYN stock opened at $20.94 on Friday. The stock has a market cap of $3.46 billion, a P/E ratio of -6.50 and a beta of 1.09. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The company’s 50 day moving average is $18.45 and its two-hundred day moving average is $18.11.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the firm posted ($1.05) earnings per share. Research analysts expect that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of large investors have recently bought and sold shares of DYN. Hilton Head Capital Partners LLC purchased a new stake in shares of Dyne Therapeutics in the first quarter valued at about $26,000. Strs Ohio purchased a new position in Dyne Therapeutics during the fourth quarter worth about $51,000. Aster Capital Management DIFC Ltd purchased a new position in Dyne Therapeutics during the fourth quarter worth about $84,000. Steward Partners Investment Advisory LLC lifted its position in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after purchasing an additional 7,697 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on DYN shares. HC Wainwright decreased their price objective on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Chardan Capital reissued a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a report on Monday, March 9th. Evercore set a $33.00 target price on Dyne Therapeutics in a research report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Finally, TD Cowen assumed coverage on Dyne Therapeutics in a research report on Friday. They set a “buy” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $34.17.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.